10 November, 2020 | ChargePoint Technology
The pandemic of 2020 has not only affected the overall pharmaceutical supply chain but more specifically, the supply of APIs from China across the globe. With the closure of many factories in China following the outbreak of Covid-19, the industry has had to adjust to overcome its reliance of APIs from China.
With an increase in the critical drug and API manufacturing and the rush to develop new medicines, including a vaccine against Covid-19, manufacturers are looking at an increased need for sterile manufacturing capabilities.
In this article in World Pharma Today, we discuss this trend in more detail and how this has an impact on manufacturing highly potent APIs (HPAPIs) in India